Absolute Risk Reduction (ARR): the absolute difference in the percentage of patients who did not develop grade 4 neutropenia in the test group versus the control group.

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial, ...

The Food and Drug Administration (FDA) has approved Xifyrm ™ (meloxicam injection) for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID ...